EarlySense will use $15 million from a funding round to bring to the market an FDA-cleared oxygen saturation component for its patient-monitoring system. The device allows the continuous, automatic tracking of oxygen levels in the blood and monitors movement to help prevent bedsores, which can increase the risk of hospital-acquired infections.